Lu Gan
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Cancer Research top 1%
- MicroRNA in disease regulation
Papers in
-
- Extracellular vesicles in disease 18
- RNA Interference and Gene Delivery 14
-
- Nanoplatforms for cancer theranostics 35
- Co-authors
- Xiangliang Yang (57 shared papers)Tuying Yong (36 shared papers)Nana Bie (20 shared papers)Xiaoqiong Zhang (16 shared papers)Zhaohan Wei (23 shared papers)Guiting Zhan (9 shared papers)Haiping He (13 shared papers)Zhizhen Ye (13 shared papers)
- Journals
- ACS Applied Materials & Interfaces (7 papers)Advanced Science (5 papers)Theranostics (5 papers)Nature Communications (4 papers)Journal of Controlled Release (4 papers)
- Partner nations
- ChinaUnited StatesNew Zealand
In The Last Decade
Lu Gan
176 papers receiving 7.2k citations
Lu Gan's Hit Papers
Peers
Comparison fields: 5 of 159
- Biomaterials 1.2k
- Cancer Research 1.1k
- Biomedical Engineering 2.4k
- Molecular Biology 3.2k
- Immunology 824
Countries citing papers authored by Lu Gan
This map shows the geographic impact of Lu Gan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Gan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Gan more than expected).
Fields of papers citing papers by Lu Gan
This network shows the impact of papers produced by Lu Gan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Gan. The network helps show where Lu Gan may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Gan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 185 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy Hit paper breakdown → | 2019 | 698 |
| 2 | 2018 | 300 | |
| 3 | Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles Hit paper breakdown → | 2021 | 277 |
| 4 | 2020 | 251 | |
| 5 | Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts Hit paper breakdown → | 2022 | 209 |
| 6 | 2010 | 205 | |
| 7 | 2019 | 192 | |
| 8 | 2020 | 168 | |
| 9 | 2001 | 156 | |
| 10 | 2011 | 151 | |
| 11 | 2017 | 122 | |
| 12 | 2016 | 117 | |
| 13 | 2021 | 117 | |
| 14 | 2015 | 116 | |
| 15 | 2018 | 105 | |
| 16 | 2021 | 104 | |
| 17 | 2022 | 95 | |
| 18 | 2020 | 94 | |
| 19 | 2017 | 92 | |
| 20 | 2018 | 87 |
About Lu Gan
Lu Gan is a scholar working on Molecular Biology, Biomedical Engineering, Materials Chemistry, Biomaterials and Immunology, having authored 185 papers that have together received 7.2k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (35 papers), Nanoparticle-Based Drug Delivery (24 papers), Extracellular vesicles in disease (18 papers), RNA Interference and Gene Delivery (14 papers), MicroRNA in disease regulation (10 papers), Immunotherapy and Immune Responses (9 papers), Perovskite Materials and Applications (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Biomaterials (1.2k citations), Cancer Research (1.1k citations), Biomedical Engineering (2.4k citations), Molecular Biology (3.2k citations) and Immunology (824 citations). Lu Gan has collaborated with scholars based in China, United States and New Zealand. Frequent co-authors include Xiangliang Yang, Tuying Yong, Nana Bie, Xiaoqiong Zhang, Zhaohan Wei, Guiting Zhan, Haiping He, Zhizhen Ye, Jun Hu and Abdul Hakeem. Their work appears in journals such as ACS Applied Materials & Interfaces, Advanced Science, Theranostics, Nature Communications and Journal of Controlled Release.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.